Active	Status	Sponsor type	Region	Phase	Filter
2 Active 10 Inactive 12 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Kurman, Michael
NCT04886622: A Study of DT2216 in Relapsed/Refractory Malignancies	Completed	1	20	US	DT2216	Dialectic Therapeutics, Inc	Solid Tumor, Hematologic Malignancy	11/23	11/23
NCT04319757: ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors	Completed	1	12	US, RoW	ACE1702, Cyclophosphamide, Fludarabine	Acepodia Biotech, Inc.	Locally Advanced Solid Tumor, Metastatic Cancer, Solid Tumor, HER2-positive Gastric Cancer, HER2-positive Metastatic Breast Cancer	07/24	07/24